<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A dog that was treated with <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>-<z:chebi fb="0" ids="9328">sulfadiazine</z:chebi> and fenbendazole developed transient <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:hpo ids='HP_0003674'>onset</z:hpo> of bone marrow <z:mpath ids='MPATH_58'>aplasia</z:mpath> at 14 days after initiation of treatment and remission of it after cessation of treatment suggested that the <z:mpath ids='MPATH_58'>aplasia</z:mpath> was drug-induced </plain></SENT>
<SENT sid="2" pm="."><plain>A hematologically <z:mpath ids='MPATH_458'>normal</z:mpath> dog treated with the same drug combination failed to develop hematologic <z:e sem="disease" ids="C0334044" disease_type="Neoplastic Process" abbrv="">dyscrasia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Because of the potential toxic effects of <z:chebi fb="0" ids="45924">trimethoprim</z:chebi>-<z:chebi fb="0" ids="9328">sulfadiazine</z:chebi> and/or fenbendazole, animals under treatment with this combination should be monitored by use of periodic CBC </plain></SENT>
</text></document>